The CEO of a B.C. biotechnology company says the treatment his firm has developed for COVID-19 is sitting on shelves while people continue to die, despite it being approved for use by Health Canada in the fall.
This story was published on CBC News. For the rest of the story please read the story right here https://www.cbc.ca/news/politics/abcellera-bamlanivimab-carl-hansen-kapelos-1.5974126?cmp=rss.
This post was originally published on this site